SB 242235 is a potent and selective inhibitor of p38 MAP kinase, making it a candidate therapeutic for diseases driven by inflammatory cytokines. It has been utilized in research to investigate cytokine signaling pathways in both cellular (in vitro) and animal (in vivo) models of inflammation and autoimmune disorders.